Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Hunter Biotechnology Inc., Zhejiang Hangzhou 310051, China.
Phytomedicine. 2024 Oct;133:155914. doi: 10.1016/j.phymed.2024.155914. Epub 2024 Aug 5.
Bufonis Venenum (BV) is a traditional animal-based Chinese medicine with therapeutic effects against cancer. However, its clinical use is significantly restricted due to associated cardiovascular risks. BV's value in China's market is typically assessed based on "content priority," focusing on indicator components. However, these components of BV possess both antitumor activity and toxicity, and the correlation between the antitumor activity and toxicity of BV has not yet been elucidated.
This study employs an integrated multi-omics approach to identify bufadienolide Q-markers and explore the correlation between BV's antitumor activity and toxicity. The aim is to establish a more comprehensive method for BV's quality.
Normal zebrafish and HepG2 xenograft zebrafish were chosen as activity and toxicity evaluation models. Ultra-high performance liquid chromatography (UHPLC) coupled with a linear ion trap orbitrap (LTQ-Orbitrap) mass spectrometry was used to quantify eight batches of BV and key "toxic and effective" components were screened out. Transcriptomic and metabolomic analyses were performed to elucidate the regulatory mechanisms underlying the antitumor activity and cardiovascular toxicity of the key components in BV.
Eight key "toxic and effective" compounds were identified: resibufogenin, cinobufagin, arenobufagin, bufotalin, bufalin, gamabufotalin, desacetylcinobufagin, and telocinobufagin. The findings showed that bufalin and cinobufagin interfered with calcium homeostasis through CaV and CaSR, induced cardiotoxicity, and upregulated CASP9 to activate myocardial cell apoptosis. However, desacetylcinobufagin exhibited greater potential in terms of anti-tumor effects. Combining the results of untargeted and targeted metabolomics revealed that desacetylcinobufagin could have a callback effect on differential lipids and correct abnormal energy and amino acid metabolism caused by cancer, similar to cinobufagin and bufalin. Microscale thermophoresis (MST) ligand binding measurements also showed that the binding of desacetylcinobufagin to GPX4 has a more potent ability to induce ferroptosis in tumor cells compared to cinobufagin.
An innovative evaluation method based on the zebrafish was developed to investigate the relationship between the toxicity and efficacy of BV. This study identified toxicity and activity Q-markers and explored the mechanism between the two effects of BV. The research data could offer valuable insights into the efficacy of BV. Additionally, desacetylcinobufagin, an active ingredient with low toxicity, was found to enhance the quality of BV.
蟾酥是一种具有抗癌作用的传统动物源性中药,但由于其心血管风险,其临床应用受到很大限制。中国市场通常基于“含量优先”来评估蟾酥的价值,重点关注指标成分。然而,这些蟾酥成分既具有抗肿瘤活性又具有毒性,蟾酥的抗肿瘤活性和毒性之间的相关性尚未阐明。
本研究采用整合的多组学方法来鉴定蟾毒配基 Q 标志物,并探讨蟾酥抗肿瘤活性和毒性之间的相关性。目的是建立更全面的蟾酥质量评价方法。
选择正常斑马鱼和 HepG2 异种移植斑马鱼作为活性和毒性评价模型。采用超高效液相色谱(UHPLC)-线性离子阱轨道阱(LTQ-Orbitrap)质谱联用技术对 8 批蟾酥进行定量分析,筛选出关键的“毒性有效”成分。进行转录组学和代谢组学分析,以阐明关键成分在蟾酥抗肿瘤活性和心血管毒性中的调控机制。
鉴定出 8 种关键的“毒性有效”化合物:脂蟾毒配基、华蟾酥毒基、蟾毒灵、蟾毒它灵、蟾毒它里定、沙蟾毒精、去乙酰华蟾毒精和 telocinobufagin。研究结果表明,蟾毒配基和华蟾酥毒基通过 CaV 和 CaSR 干扰钙稳态,引起心脏毒性,并上调 CASP9 激活心肌细胞凋亡。然而,去乙酰华蟾毒精在抗肿瘤方面具有更大的潜力。结合非靶向和靶向代谢组学的结果表明,去乙酰华蟾毒精可以对差异脂质产生回调作用,并纠正癌症引起的异常能量和氨基酸代谢,与华蟾酥毒基和蟾毒配基相似。微量热泳动(MST)配体结合测量也表明,与华蟾酥毒基相比,去乙酰华蟾毒精与 GPX4 的结合更能诱导肿瘤细胞发生铁死亡。
本研究开发了一种基于斑马鱼的创新评价方法,研究了蟾酥毒性与疗效之间的关系。本研究鉴定了毒性和活性 Q 标志物,并探讨了蟾酥两方面作用的机制。研究数据可为蟾酥的疗效提供有价值的见解。此外,还发现低毒性的活性成分去乙酰华蟾毒精可以提高蟾酥的质量。